Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
SINGAPORE, April 17, 2018 -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new data from a study of the use of varlitinib in hepatocellular carcinoma (HCC) at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois.
| Details of the poster are as below: | ||
| Session: | Experimental and Molecular Therapeutics | |
| Poster #: | 3992 / 26 | |
| Section: | 41 | |
| Title: | Varlitinib demonstrates tumor regression and vessel normalization in ErbB-dependent and mutated beta-catenin hepatocellular carcinoma patient-derived xenograft model | |
The pre-clinical study was conducted in collaboration with the National Cancer Centre Singapore (NCCS) and was led by Professor The Huynh Hung, Principal Investigator at NCCS’ Laboratory of Molecular Endocrinology. The study was designed to demonstrate the efficacy of varlitinib in HCC patient-derived xenograft (PDX) models and to study the molecular mechanisms of varlitinib-mediated tumor suppression and its anti-angiogenic potential. In addition, the study sought to identify gene signatures associated with efficacy of varlitinib by transcriptome and gene expression analyses.
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumor growth. Varlitinib is currently being studied in gastric, biliary tract, breast and colorectal cancers. Varlitinib has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
Media and IR contacts Chris Fang ASLAN Pharmaceuticals Tel: +886 2 2758 3333 Email: [email protected] Emma Thompson / Stephanie Tan Spurwing Communications Tel: +65 6340 7287 Email: [email protected] Robert H Uhl Westwicke Partners Tel: +1 858 356 5932 Email: [email protected]
